September 30, 2020 – The Cooley’s Anemia Foundation’s 2020 Gala, scheduled for Wednesday, October 28 at 6:30 pm (Eastern) will be held entirely online this year in order to ensure the safety of all attendees during the current pandemic. In addition to our usual Gala program, the evening will include a Live Auction and a […]
September 29, 2020 – Taro Pharmaceutical Industries Ltd. has launched specialty generic deferiprone (Ferriprox®) 500 mg tablets in the U.S. Further information can be found in the press release at: https://www.businesswire.com/news/home/20200928005649/en/Taro-Launches-Specialty-Generic-Deferiprone-Tablets-500mg-in-the-U.S At launch, Taro’s deferiprone tablets will be exclusively dispensed by BioPlus® Specialty Pharmacy. For more information, visit Taro Cares at www.tarocares.com or call 1-888-292-0744.
September 20, 2020 – Today is the day! The Cooley’s Anemia Foundation’s annual Care Walk is finally here, and we are thrilled to know that so many people across the country are Care Walking in honor of individuals with thalassemia. As you know, Care Walk is the Cooley’s Anemia Foundation’s largest annual fundraising event, bringing […]
September 16, 2020 – This weekend, thousands of supporters in cities across the U.S. will be participating in our Care Walk in honor and support of all those living with the challenges of thalassemia. Care Walk is the Cooley’s Anemia Foundation’s largest annual fundraising event, bringing together the thalassemia community and its supporters around the […]
September 9, 2020 – The Cooley’s Anemia Foundation (CAF) has received a five-year Cooperative Agreement from the Centers for Disease Control and Prevention (CDC). This funding will be used to support patient outreach efforts, health messaging for the thalassemia patient/family community, and evidence-based training for thalassemia healthcare providers. The new Cooperative Agreement will go into […]
September 2, 2020 – CRISPR Therapeutics and Vertex are conducting a Phase 1/2 study of gene editing in patients with transfusion-dependent beta-thalassemia. This trial will investigate whether increasing the production of fetal hemoglobin through gene editing can reduce or eliminate the need for blood transfusions. It will also investigate the safety of this treatment. Participating […]
